<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open Respir Res</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open Respir Res</journal-id><journal-id journal-id-type="pmc-domain-id">2615</journal-id><journal-id journal-id-type="pmc-domain">bmjresp</journal-id><journal-id journal-id-type="publisher-id">bmjopenrespres</journal-id><journal-title-group><journal-title>BMJ Open Respiratory Research</journal-title></journal-title-group><issn pub-type="epub">2052-4439</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10186431</article-id><article-id pub-id-type="pmcid-ver">PMC10186431.1</article-id><article-id pub-id-type="pmcaid">10186431</article-id><article-id pub-id-type="pmcaiid">10186431</article-id><article-id pub-id-type="pmid">37130651</article-id><article-id pub-id-type="doi">10.1136/bmjresp-2022-001478</article-id><article-id pub-id-type="publisher-id">bmjresp-2022-001478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Chronic Obstructive Pulmonary Disease</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>2215</subject></subj-group></article-categories><title-group><article-title>Undiagnosed and &#8216;overdiagnosed&#8217; COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib id="author-66301805" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7034-0615</contrib-id><name name-style="western"><surname>Perret</surname><given-names initials="J">Jennifer</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib id="author-101857647" contrib-type="author"><name name-style="western"><surname>Yip</surname><given-names initials="SWS">Sui Wah Sean</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib id="author-101857636" contrib-type="author"><name name-style="western"><surname>Idrose</surname><given-names initials="NS">Nur Sabrina</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib id="author-91565319" contrib-type="author"><name name-style="western"><surname>Hancock</surname><given-names initials="K">Kerry</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib id="author-66201941" contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9954-0538</contrib-id><name name-style="western"><surname>Abramson</surname><given-names initials="MJ">Michael J</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib id="author-66201907" contrib-type="author"><name name-style="western"><surname>Dharmage</surname><given-names initials="SC">Shyamali C</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib id="author-33505410" contrib-type="author"><name name-style="western"><surname>Walters</surname><given-names initials="EH">E Haydn</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib id="author-101857609" contrib-type="author"><name name-style="western"><surname>Waidyatillake</surname><given-names initials="N">Nilakshi</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff9" ref-type="aff">9</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution content-type="department">Allergy and Lung Health Unit, Melbourne School of Population and Global Health</institution>, <institution specific-use="Ringgold_2281">The University of Melbourne</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Respiratory and Sleep Medicine</institution>, <institution specific-use="Ringgold_3805">Austin Health</institution>, <addr-line content-type="city">Heidelberg</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff3"><label>3</label><institution>Institute for Breathing and Sleep (IBAS)</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff4"><label>4</label><institution content-type="department">Melbourne School of Population and Global Health</institution>, <institution specific-use="Ringgold_2281">The University of Melbourne</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Centre for Food and Allergy Research</institution>, <institution specific-use="Ringgold_34361">Murdoch Children's Research Institute</institution>, <addr-line content-type="city">Parkville</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff6"><label>6</label><institution specific-use="Ringgold_605166">Chandlers Hill Surgery</institution>, <addr-line content-type="city">Happy Valley</addr-line>, <addr-line content-type="state">South Australia</addr-line>, <country>Australia</country></aff><aff id="aff7"><label>7</label><institution content-type="department">School of Public Health and Preventive Medicine</institution>, <institution specific-use="Ringgold_2541">Monash University</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff8"><label>8</label><institution content-type="department">School of Medicine</institution>, <institution specific-use="Ringgold_3925">University of Tasmania</institution>, <addr-line content-type="city">Hobart</addr-line>, <addr-line content-type="state">Tasmania</addr-line>, <country>Australia</country></aff><aff id="aff9"><label>9</label><institution content-type="department">Department of Medical Education</institution>, <institution specific-use="Ringgold_2281">The University of Melbourne</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Jennifer Perret; <email>jennifer.perret@unimelb.edu.au</email></corresp><fn fn-type="other"><p>JP and SWSY are joint first authors.</p></fn><fn fn-type="other"><p>EHW and NW are joint senior authors.</p></fn></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>4</month><year>2023</year></pub-date><volume>10</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">426206</issue-id><elocation-id>e001478</elocation-id><history><date date-type="received"><day>03</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>17</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-17 10:26:49.763"><day>17</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2023</copyright-year><ali:free_to_read/><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-04-20">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bmjresp-2022-001478.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bmjresp-2022-001478.pdf"/><abstract><sec><title>Background</title><p>Despite chronic obstructive pulmonary disease (COPD) being a major global cause of mortality and hospitalisation, it is often undiagnosed or inaccurately diagnosed in clinical settings.</p></sec><sec><title>Objective</title><p>To systematically synthesise all peer-reviewed papers from primary healthcare settings that have reported data on: (1) undiagnosed COPD, that is, patients with respiratory symptoms and postbronchodilator airflow obstruction consistent with COPD, without a formal clinician&#8217;s diagnosis of COPD either documented in health records or reported by patients and (2) &#8216;overdiagnosed COPD&#8217;, that is, clinician&#8217;s diagnosis without postbronchodilator airflow obstruction.</p></sec><sec><title>Methods</title><p>Studies investigating these diagnostic metrics in patients from primary healthcare clinics (according to predefined inclusion/exclusion criteria) were sourced from Medline and Embase and assessed for bias (Johanna Briggs Institute tools for prevalence studies and case series). Meta-analyses of studies of adequate sample size used random effect modelling stratified by risk factor categories.</p></sec><sec><title>Results</title><p>Of 26 eligible articles, 21 cross-sectional studies investigated 3959 cases of spirometry-defined COPD (with or without symptoms), and 5 peer-reviewed COPD case series investigated 7381 patients. The prevalence of spirometry-confirmed COPD without a diagnosis documented in their health records was 14%&#8211;26% in studies of symptomatic smokers (N=3). 1 in 4 patients taking inhaled therapies (25% (95% CI 22% to 28%), N=2) and 1 in 6 smokers irrespective of symptoms (16% (95% CI 14% to 18%), N=6) fulfilled diagnostic spirometry criteria but did not report receiving a COPD-related diagnosis. In an adequately powered series of COPD cases documented in primary healthcare records (N=4), only between 50% and 75% of subjects had any airflow obstruction on postbronchodilator spirometry performed by study researchers, therefore, COPD was clinically &#8216;overdiagnosed&#8217; in 25%&#8211;50% of subjects.</p></sec><sec><title>Discussion</title><p>Although data were heterogeneous and of modest quality, undiagnosed COPD was common in primary healthcare, especially for symptomatic smokers and patients treated with inhaled therapies. In contrast, frequent COPD &#8216;overdiagnosis&#8217; may represent treatment of asthma/reversible component or another medical diagnosis.</p></sec><sec><title>PROSPERO registration number</title><p>CRD42022295832.</p></sec></abstract><kwd-group><kwd>COPD epidemiology</kwd><kwd>Clinical epidemiology</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="funding-1"><funding-source><institution-wrap><institution>NHMRC of Australia</institution></institution-wrap></funding-source><award-id>APP1159090</award-id></award-group><award-group id="funding-2"><funding-source><institution-wrap><institution>NHMRC of Australia</institution></institution-wrap></funding-source><award-id>APP1193993</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><sec><title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title><list list-type="bullet"><list-item><p>Inadequate diagnosis of chronic obstructive pulmonary disease (COPD) is common, however, previous reviews have only narratively synthesised the evidence and not focused on primary healthcare (eg, general practice) patient populations in the &#8216;real world&#8217;; nor have they calculated the absolute proportions undiagnosed with clinical COPD in the community.</p></list-item></list></sec><sec><title>WHAT THIS STUDY ADDS</title><list list-type="bullet"><list-item><p>This first systematic review and meta-analysis of studies investigating COPD diagnosis in primary healthcare settings has documented the prevalence of undiagnosed COPD in 14%&#8211;26% of symptomatic smokers and in one-quarter of patients taking inhaled therapies. In contrast, there was a 25%&#8211;50% prevalence of COPD &#8216;overdiagnosis&#8217; where clinician-labelled patients having COPD did not have objective evidence of postbronchodilator airflow obstruction, also highlighting the known underutilisation of spirometry globally.</p></list-item></list></sec><sec><title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title><list list-type="bullet"><list-item><p>The summary prevalence estimates of undiagnosed (or unrecognised) COPD inform clinicians in primary healthcare of the potential opportunities to uncover COPD cases and implement secondary preventive strategies and other important aspects of COPD management. On the other hand, to minimise COPD &#8216;overdiagnosis&#8217; and prescribing of non-indicated inhaled therapies, patients first presenting with suspected COPD should be further investigated to elucidate the underlying true diagnosis.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Accurately diagnosing chronic obstructive pulmonary disease (COPD)&#8212;a leading cause of global mortality<xref rid="R1" ref-type="bibr">1</xref> non-fatal respiratory health burden and risk of lung cancer<xref rid="R2" ref-type="bibr">2</xref>&#8212;is needed for optimal disease management. As the most widely used strategic report for COPD management, the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) states that the presence of postbronchodilator (post-BD) airflow obstruction is mandatory for establishing the diagnosis of COPD.<xref rid="R3" ref-type="bibr">3</xref> Clinical suspicion is raised in patients who have respiratory symptoms (eg, shortness of breath, chronic cough or sputum production, recurrent lower respiratory tract infections) and/or a known risk factor (eg, history of smoking &#8805;10 pack-years, occupational exposure to vapour/gas/dust/fumes, familial COPD or low birth weight). Other local guidelines may be subtly different, but in general concern adult patients (&gt;35&#8211;40 years) with respiratory symptom(s), a known risk factor and for whom post-BD spirometry is recommended to confirm the clinical diagnosis.<xref rid="R4" ref-type="bibr">4&#8211;7</xref></p><p>The recent Lancet Commission has re-emphasised spirometry as the first confirmatory test to guide diagnosis,<xref rid="R8" ref-type="bibr">8</xref> but its consistent underuse remains a global problem.<xref rid="R9" ref-type="bibr">9</xref> For many patients with COPD, the diagnosis is first made after admission to hospital during an acute exacerbation,<xref rid="R10" ref-type="bibr">10&#8211;12</xref> usually when there has already been substantial lung damage and chronic treatments are poorly effective. Concerningly, opportunities for these symptomatic patients to have the diagnosis confirmed at an earlier stage are commonly missed<xref rid="R13" ref-type="bibr">13</xref> so their COPD has potentially remained unrecognised for many years. Conversely, symptomatic individuals may be managed as having COPD but do not have obstructed spirometry&#8212;this has been termed &#8216;COPD overdiagnosis&#8217; by the respiratory field.<xref rid="R14" ref-type="bibr">14</xref></p><p>Narrative reviews have attempted to contextualise the magnitude of these diagnostic issues globally.<xref rid="R15" ref-type="bibr">15&#8211;17</xref> However, these reviews mainly focused on studies surveying participants from general community populations when there was some uncertainty as to whether such people had the opportunity to be assessed by a clinician from a healthcare service to confirm the diagnosis.<xref rid="R18" ref-type="bibr">18</xref> The reviews also did not focus on the absolute proportions of subjects undiagnosed in the whole population sample who had spirometry-defined COPD measured by researchers but no clinician diagnosis of COPD on their health record and/or by self-report. Nor did they separate this metric from relative COPD underdiagnosis among only subjects with spirometry-defined COPD, which could seem inflated in the setting of a relatively low COPD prevalence. To illustrate both underdiagnosis figures, for a primary healthcare (PHC) population in which the prevalence of spirometry-defined COPD turned out to be 6.0%, if 95% of the 6.0% were undiagnosed (relative underdiagnosis), then this means that 5.75% of that PHC population did not have a clinician diagnosis of COPD (absolute percentage undiagnosed).<xref rid="R19" ref-type="bibr">19</xref></p><p>Furthermore, previous reviews<xref rid="R15" ref-type="bibr">15&#8211;17</xref> did not investigate the hypothesis that high-risk populations such as smokers, and those on inhaled medicines and/or who have respiratory symptoms may differ in their estimates of COPD underdiagnosis and overdiagnosis. It is important to estimate the prevalence of undiagnosed COPD within these at-risk populations to better understand the potential extent of undermanaged disease in patients of PHC settings. While conversely, the occurrence of COPD &#8216;overdiagnosis&#8217; highlights the issues of empirically treating patients and risk of prescribing non-indicated medicines.</p><p>Therefore, using post-BD airflow obstruction as the mandatory criterion to establish a diagnosis of COPD,<xref rid="R3" ref-type="bibr">3 20</xref> our overall aim was to systematically synthesise the evidence in peer-reviewed publications from PHC settings to quantify the issues of COPD underdiagnosis (absolute and relative proportions) and COPD overdiagnosis. Specifically, we aimed to estimate the prevalence of: (1) undiagnosed COPD in the whole samples based on the presence of post-BD airflow obstruction, and in the presence of respiratory symptom(s) and/or risk factor(s); (2) relative COPD underdiagnosis only among those found by researchers to have spirometric evidence of COPD and (3) COPD &#8216;overdiagnosis&#8217; in patients labelled as having COPD, but without airflow obstruction on post-BD spirometry. We also aimed to describe the characteristics of participants who were underdiagnosed and/or overdiagnosed, where such data were available.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>A systematic review protocol was developed and registered in PROSPERO: the international prospective register of systematic reviews (registration number CRD42022295832).<xref rid="R21" ref-type="bibr">21</xref> The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklists and flow diagram were used for reporting.<xref rid="R22" ref-type="bibr">22</xref> The research question was formulated using the SPIDER tool: Sample (general practice populations); Phenomenon of Interest (COPD prevalence and its underdiagnosis and overdiagnosis); Design (either cross-sectional prevalence study or COPD case series); Evaluation (proportions underdiagnosed and overdiagnosed) and Research type (quantitative).</p><sec id="s2-1"><title>Search strategy</title><p>Two electronic databases, Medline (OVID) and Embase, were systematically searched up to 4 January 2022. The search strategy was codeveloped with an experienced librarian consisting of MeSH terms and keywords for &#8220;COPD&#8221;, &#8220;under-diagnosis&#8221;, &#8220;over-diagnosis&#8221; and &#8220;misdiagnosis&#8221; including synonyms and acronyms (<xref rid="SP1" ref-type="supplementary-material">online supplemental methods S1</xref>). Summary tables and reference lists in articles were manually searched for further eligible studies. The inclusion and main exclusion criteria were developed based on the knowledge gaps identified and the most widely accepted method for confirming a COPD diagnosis, that is, fixed airflow obstruction on post-BD spirometry. We excluded non-English papers (given time constraints/costs) and conference abstracts (given limited information and inability to perform detailed risk assessments).</p><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjresp-2022-001478.supp1</object-id><label>Supplementary data</label><p>
<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" id="SS1" xlink:href="bmjresp-2022-001478supp001.pdf" content-type="local-data"/>
</p></supplementary-material><sec id="s2-1-1"><title>Inclusion criteria</title><list list-type="bullet"><list-item><p>PHC (ie, general practice, family health, community health) settings.</p></list-item><list-item><p>COPD defined using post-BD spirometry as the diagnostic criterion; synonymous with the term &#8216;spirometry-defined COPD&#8217;.</p></list-item><list-item><p>Study contained at least one prevalence estimate of COPD underdiagnosis/overdiagnosis/misdiagnosis including:</p><list list-type="order"><list-item><p>Prevalence undiagnosed among those found by researchers to have spirometry-defined COPD (also referred to as COPD underdiagnosis).</p></list-item><list-item><p>Prevalence overdiagnosed among those labelled by the treating clinician as having COPD, but without obstructive post-BD spirometry when tested by researchers.</p></list-item></list></list-item></list></sec><sec id="s2-1-2"><title>Exclusion criteria</title><list list-type="bullet"><list-item><p>Post-BD forced expiratory volume in 1 s (FEV<sub>1</sub>)/forced vital capacity (FVC) not presented or was not the diagnostic criterion.</p></list-item><list-item><p>Not a PHC setting (ie, general population, specialised populations, specialised clinics or hospital settings).</p></list-item><list-item><p>Study analysed prior to 2001 (first publication of GOLD guidelines).<xref rid="R20" ref-type="bibr">20</xref></p></list-item><list-item><p>Narrative reviews, case reports, study design protocol or no primary data.</p></list-item><list-item><p>Articles published in languages other than English.</p></list-item><list-item><p>Animal experiments, conference abstracts and unpublished studies.</p></list-item></list></sec></sec><sec id="s2-2"><title>Article selection</title><p>Following duplicate-publication removal, two authors (SWSY and JP) independently screened all titles and abstracts in Covidence systematic review software.<xref rid="R23" ref-type="bibr">23</xref> Articles selected for full-text review were retrieved and assessed against the inclusion/exclusion criteria (SWSY and NSI). All disagreements were resolved through discussions between SWSY, NSI, NW and JP.</p><p>There were efforts to include all available studies where prevalence data were reported, even if COPD underdiagnosis and/or overdiagnosis was not the main research question.</p></sec><sec id="s2-3"><title>Quality assessment</title><p>The quality of included articles was assessed using the Johanna Briggs Institute (JBI) quality assessment tool checklist for the methodology of prevalence studies<xref rid="R24" ref-type="bibr">24</xref> and case series.<xref rid="R25" ref-type="bibr">25</xref> These tools enabled the identification of poorer quality studies across specific categories including sampling frame and recruitment, sample size, measurement reliability and clarity of reporting. A calculation was performed to assess the adequacy of the sample size used to estimate COPD prevalence, which could bias the estimates.<xref rid="R26" ref-type="bibr">26 27</xref></p></sec><sec id="s2-4"><title>Data extraction (and calculations)</title><p>Two authors (SWSY and JP) independently extracted and discussed the following information from the papers selected: first author, publication year, study name, country, study design, participant number and % of eligible, sampling/selection, number/type of PHC clinics/general practices, gender/sex/age, prevalence of spirometry-defined COPD, prevalence of undiagnosed COPD in the study population and also relative to those found to have spirometry-defined COPD, prevalence overdiagnosed in those labelled with COPD and qualitative descriptions of characteristics of those underdiagnosedor overdiagnosed, where available.</p><p>While many underdiagnosis/overdiagnosis figures could be directly extracted from the individual studies themselves, some figures needed to be calculated from the data reported (as indicated in tables). SWSY and JP calculated the absolute prevalence of undiagnosed COPD from the entire population studied (see definitions). Furthermore, the percentage diagnosed was calculated to be 100% minus the percentage of COPD underdiagnosis (ie, 25% relative undiagnosed would equate to 75% diagnosed accurately).<xref rid="R17" ref-type="bibr">17</xref> Contact with authors of eligible studies was not required for this purpose.</p><p>After preliminary data extraction, the studies were classified by design. The cross-sectional prevalence studies were further divided into the following broad risk-indicator categories given the heterogeneity: adults &#8805;40 years, smokers with symptoms, smokers irrespective of symptoms, respiratory symptoms irrespective of smoking and other high-risk groups. These factors were important to consider as they highlighted subsets of individuals who were more prone to developing COPD or potentially being prescribed non-indicated therapies.</p></sec><sec id="s2-5"><title>Definitions used to extract data from research studies*</title><sec id="s2-5-1"><title>Prevalence of spirometry-defined COPD</title><p>
<disp-formula id="E1"><mml:math id="eqn1" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">O</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">j</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p></sec><sec id="s2-5-2"><title>Prevalence of undiagnosed COPD in entire study population (absolute proportion)</title><p>
<disp-formula id="E2"><mml:math id="eqn2" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mfrac linethickness="0"><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>&#8722;</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">j</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p></sec><sec id="s2-5-3"><title>Prevalence of underdiagnosis in those with spirometry-defined COPD (relative proportion)</title><p>
<disp-formula id="E3"><mml:math id="eqn3" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mfrac linethickness="0"><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>&#8722;</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p></sec><sec id="s2-5-4"><title>Prevalence of &#8216;overdiagnosis&#8217; in those with a prior clinician&#8217;s diagnosis of COPD</title><p>
<disp-formula id="E4"><mml:math id="eqn4" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mfrac linethickness="0"><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">O</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac linethickness="0"><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>
</p><p>Consistent with global guidelines,<xref rid="R20" ref-type="bibr">20</xref> post-BD spirometry defined the lung function feature of COPD based on FEV<sub>1</sub>/FVC ratio, either using a fixed cut-off of 0.7<xref rid="R20" ref-type="bibr">20</xref> and/or lower limit of statistical normal (LLN). Clinical COPD was further defined by a combination of post-BD airflow obstruction and respiratory symptom(s)&#177;known risk factor(s).<xref rid="R20" ref-type="bibr">20</xref></p></sec></sec><sec id="s2-6"><title>Data analysis</title><p>Statistical analysis used the &#8216;metaprop&#8217; command<xref rid="R28" ref-type="bibr">28</xref> within Stata SE V.16 software (Stata), which required data on percentage, case numbers and total subject numbers for the prevalence figures studied.</p><p>A meta-analysis was conducted using random effect modelling stratified by risk factor categories. While overall and subgroup estimates with 95% CIs were calculated, a pooled estimate was only reported if the degree of heterogeneity (I<sup>2</sup>) was &lt;75% or if the 95% CI of all studies within a risk category clearly overlapped. Studies that had smaller sample sizes than those expected to estimate COPD prevalence accurately were omitted in a sensitivity analysis and these forest plots have been presented. These calculations<xref rid="R26" ref-type="bibr">26 27</xref> performed as part of the risk-of-bias assessment (JP), retrospectively looked at the number of participants required to observe the prevalence found by the study researchers with a predefined precision.</p></sec><sec id="s2-7"><title>Patient and public involvement</title><p>Patients or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Of 1294 titles and abstracts screened, 207 full-text articles were reviewed, and 181 records excluded based on inclusion/exclusion criteria (<xref rid="F1" ref-type="fig">figure 1</xref>). Of 26 remaining articles, 21 were cross-sectional prevalence studies with 3959 cases of spirometry-defined COPD from a total of 19 423 subjects tested.<xref rid="R19" ref-type="bibr">19 29&#8211;48</xref> Just one additional study was identified from a manual search of the articles,<xref rid="R39" ref-type="bibr">39</xref> and another was excluded as spirometry was part of the diagnostic workup and informed the clinician&#8217;s diagnosis.<xref rid="R49" ref-type="bibr">49</xref> All 21 articles provided data on undiagnosed COPD, while 9 also provided data on COPD &#8216;overdiagnosis&#8217;. There were eight studies assessing patients with symptoms and/or taking inhaled therapies (<xref rid="T1" ref-type="table">table 1</xref>), seven assessing spirometry-defined COPD in adult smokers irrespective of symptoms (<xref rid="T2" ref-type="table">table 2</xref>), four in patient populations &#8805;40 years (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S1</xref>), one reporting on a registry and another which assessed higher-risk patients identified by a screening survey (<xref rid="T2" ref-type="table">table 2</xref>). In addition, there were 5 COPD case series reporting 7381 confirmed cases from 10 142 unique subjects,<xref rid="R50" ref-type="bibr">50&#8211;54</xref> which provided data related only to COPD &#8216;overdiagnosis&#8217; (<xref rid="T3" ref-type="table">table 3</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flow diagram.<xref rid="R22" ref-type="bibr">22</xref> BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Diseases; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjresp-2022-001478f01.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Undiagnosed clinical COPD* and its overdiagnosis using postbronchodilator spirometry: cross-sectional studies of symptomatic adults or adults taking inhaler therapies in primary healthcare settings</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Author year citation</td><td align="left" valign="bottom" rowspan="1" colspan="1">Study name location</td><td align="left" valign="bottom" rowspan="1" colspan="1">Participant<break/>no&#8224; (%eligible&#8225;), Sampling,<break/>selection, no/type of GP practices</td><td align="left" valign="bottom" rowspan="1" colspan="1">Gender<break/>Age<break/>(mean (SD) years)</td><td align="left" valign="bottom" rowspan="1" colspan="1">Prevalence of spirometry-defined COPD (%, (n/N))&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Underdiagnosis in COPD subpopulation<break/>(%, (n/N))&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Undiagnosed COPD in studied population<break/>(%, (n/N))*&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Overdiagnosis in population labelled with COPD<break/>(%, (n/N))&#167;</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="8">Smokers with symptoms</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Liang, 2018<xref rid="R29" ref-type="bibr">29</xref></td><td align="left" valign="top" rowspan="1" colspan="1">RADICALS study<break/>Australia</td><td align="left" valign="top" rowspan="1" colspan="1">N=1050 (9.8%)<break/>Consecutive; adults &gt;40 years, symptomatic ever-smokers with &#8805;2 GP visits in last 12 months; 43 urban practices</td><td align="left" valign="top" rowspan="1" colspan="1">60%&#8211;63% male<break/>Undiagnosed: 62 (10) years<break/>Diagnosed: 67(10) years</td><td align="left" valign="top" rowspan="1" colspan="1">25.9% (272/1050)</td><td align="left" valign="top" rowspan="1" colspan="1">52.2%<break/>(142/272)</td><td align="left" valign="top" rowspan="1" colspan="1">13.5% (142/1050)**</td><td align="left" valign="top" rowspan="1" colspan="1">41.2%<break/>(91/221)**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;L&#248;kke, 2012<xref rid="R37" ref-type="bibr">37</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Denmark, Sweden</td><td align="left" valign="top" rowspan="1" colspan="1">N=4049 (n/a)<break/>Adults &#8805;35 years<break/>Ever-smoker or occupational exposure plus &#8805;1 respiratory symptom<break/>No previous lung disease; 241 GPs</td><td align="left" valign="top" rowspan="1" colspan="1">51% male<break/>58 (male)<break/>57 (female)</td><td align="left" valign="top" rowspan="1" colspan="1">21.7%<break/>(878/4049) excluding BDR&gt;500 mL</td><td align="left" valign="top" rowspan="1" colspan="1">&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">21.7%<break/>(878/4049)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Sandelowsky, 2011<xref rid="R40" ref-type="bibr">40</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Stockholm, Sweden</td><td align="left" valign="top" rowspan="1" colspan="1">N=138 (69.7%)&#8224;<break/>Adults 40&#8211;75 years<break/>Ever-smoker (current or past) with an LRTI, without prior lung disease<break/>No of suburban clinics unclear</td><td align="left" valign="top" rowspan="1" colspan="1">44% male<break/>55 years<break/>(95% CI 54 to 57)</td><td align="left" valign="top" rowspan="1" colspan="1">27.5%<break/>(38/138)<break/>spirometry 4&#8211;5 weeks post-LRTI</td><td align="left" valign="top" rowspan="1" colspan="1">&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">27.5%<break/>(38/138)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Yawn, 2009<xref rid="R43" ref-type="bibr">43</xref></td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">N=1201 (93.6%)<break/>Non-consecutive; adults &gt;40 years<break/>Chronic bronchitis and &gt;10 pack-years without inhaler use or COPD confirmed by spirometry; 50 practices</td><td align="left" valign="top" rowspan="1" colspan="1">45% male<break/>52.9 (9.1) years<break/>80% white</td><td align="left" valign="top" rowspan="1" colspan="1">25.6%<break/>(308/1201)</td><td align="left" valign="top" rowspan="1" colspan="1">&#182;**</td><td align="left" valign="top" rowspan="1" colspan="1">25.6%<break/>(308/1201)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="8">Inhalers including asthma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Abramson, 2012<xref rid="R35" ref-type="bibr">35</xref></td><td align="left" valign="top" rowspan="1" colspan="1">SPIRO-GP, VIC Australia, prior to randomisation</td><td align="left" valign="top" rowspan="1" colspan="1">N=199 (12.1%)<break/>Adults 18&#8211;70 years<break/>Prescribed inhaled medication from 31 urban GP practices</td><td align="left" valign="top" rowspan="1" colspan="1">33% males<break/>54 (13) years</td><td align="left" valign="top" rowspan="1" colspan="1">45.7%<break/>(91/199)<break/>(COPD+ACO)</td><td align="left" valign="top" rowspan="1" colspan="1">58.2%<break/>(53/91)**<break/>(COPD+ACO)</td><td align="left" valign="top" rowspan="1" colspan="1">26.6%<break/>(53/199)**<break/>(COPD+ACO)</td><td align="left" valign="top" rowspan="1" colspan="1">32.1%<break/>(18/56)**<break/>(COPD+ACO)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Tinkelman, 2006<xref rid="R48" ref-type="bibr">48</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Aberdeen UK, Denver, USA</td><td align="left" valign="top" rowspan="1" colspan="1">N=597 (1&#8211;10%)&#8225;<break/>Representative; adults &#8805;40 years with history of OLD and/or receipt of inhalers last 12 months<break/>Query no of GP practices</td><td align="left" valign="top" rowspan="1" colspan="1">38.3% male 58.7 (11) years</td><td align="left" valign="top" rowspan="1" colspan="1">39.4% (235/597)** (COPD+ACO)<break/>28.6% (171/597)** (COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">62.1% (146/235)** (COPD+ACO)<break/>68.4% (117/171)** (COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">24.5% (146/597)** (COPD+ACO)<break/>19.6% (117/597)** (COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">51.6%<break/>(95/184)** (COPD+ACO)<break/>60.6%<break/>(83/137)** (COPD only)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="8">Symptoms-risk factors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Frank, 2006<xref rid="R46" ref-type="bibr">46</xref></td><td align="left" valign="top" rowspan="1" colspan="1">MAGIC study, Manchester, UK</td><td align="left" valign="top" rowspan="1" colspan="1">N=825 (&#8776;14%)<break/>Consecutive; adults &#8805;30 years<break/>Ever-smokers and/or &#8805;4 symptoms or risk factors &#8224;&#8224;; 2 GP practices</td><td align="left" valign="top" rowspan="1" colspan="1">45.3% male<break/>55.5 years</td><td align="left" valign="top" rowspan="1" colspan="1">19.8%<break/>(163/825)<break/>(GOLD stage II&#8211;IV)</td><td align="left" valign="top" rowspan="1" colspan="1">63.2%<break/>(103/163)</td><td align="left" valign="top" rowspan="1" colspan="1">12.5%<break/>(103/825)**</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hamers, 2006<xref rid="R47" ref-type="bibr">47</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">N=142 (40.6%)&#8224;<break/>&#8805;15 years old with symptoms of shortness of breath and/or cough<break/>34 urban and rural GP practices</td><td align="left" valign="top" rowspan="1" colspan="1">45.1% male<break/>46.8 (18.7) years</td><td align="left" valign="top" rowspan="1" colspan="1">25.4%<break/>(36/142)</td><td align="left" valign="top" rowspan="1" colspan="1">75%<break/>(27/36)</td><td align="left" valign="top" rowspan="1" colspan="1">19.0%<break/>(27/142)**</td><td align="left" valign="top" rowspan="1" colspan="1">70%<break/>(21/30)**</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p>*Clinical COPD if patient subjects had symptoms and spirometric evidence of COPD; undiagnosed based on an absent diagnosis in medical records except for Tinkelman <italic toggle="yes">et al</italic>.<xref rid="R48" ref-type="bibr">48</xref></p></fn><fn id="T1_FN2"><p>&#8224;COPD prevalence could be inaccurate due to insufficient sample size (<xref rid="SP1" ref-type="supplementary-material">online supplemental results E4</xref>), so have been omitted from the forest plots in a sensitivity analysis.</p></fn><fn id="T1_FN3"><p>&#8225;All % eligible figures were calculated, except when mentioned in the discussion text by Tinkelman <italic toggle="yes">et al</italic>.<xref rid="R48" ref-type="bibr">48</xref></p></fn><fn id="T1_FN4"><p>&#167;COPD was defined using the GOLD criterion, postbronchodilator forced expiratory ratio &lt;0.70, except where indicated by &#167; when the only criterion was the LLN.</p></fn><fn id="T1_FN5"><p>&#182;Percentage undiagnosed in the COPD subpopulation was 100% as the population excluded patients with a history of COPD (3 of total of 7 studies).</p></fn><fn id="T1_FN6"><p>**Data needed to be deduced and calculated from the figures given (by the present authors).</p></fn><fn id="T1_FN7"><p>&#8224;&#8224;Includes wheezing; woken by cough, chest tightness, dyspnoea; hay fever or familial asthma.<xref rid="R48" ref-type="bibr">48</xref></p></fn><fn id="T1_FN8"><p>ACO, asthma-COPD overlap; BDR, bronchodilator response; COPD, Chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner; LLN, lower limit of statistical normal; LRTI, lower respiratory tract infection; NA, not available; OLDs, obstructive lung diseases; PC, primary care.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Undiagnosed COPD* and its overdiagnosis using postbronchodilator spirometry: cross-sectional studies of smokers (irrespective of symptoms) and other high-risk patients in primary healthcare settings</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Author, year, citation</td><td align="left" valign="bottom" rowspan="1" colspan="1">Study name location</td><td align="left" valign="bottom" rowspan="1" colspan="1">Participant<break/>No&#8224; (%eligible&#8225;), Sampling,<break/>selection, no/type of GP practices</td><td align="left" valign="bottom" rowspan="1" colspan="1">Gender<break/>Age<break/>(mean (SD) years)</td><td align="left" valign="bottom" rowspan="1" colspan="1">Prevalence of spirometry-defined COPD (%, (n/N))&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Underdiagnosis in COPD subpopulation<break/>(%, (n/N))&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Undiagnosed COPD in studied population<break/>(%, (n/N))*&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Overdiagnosis in population labelled with COPD<break/>(%, (n/N))&#167;</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="8">Smoking per se (regardless of symptoms)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Stafyla, 2018<xref rid="R30" ref-type="bibr">30</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Thessaly, Greece</td><td align="left" valign="top" rowspan="1" colspan="1">N=186 (91.2%)&#8224;<break/>Convenience; adults &#8805;40 years<break/>Current or ex-smokers living near 10 urban/rural practices</td><td align="left" valign="top" rowspan="1" colspan="1">68% males<break/>62.3 (13) years</td><td align="left" valign="top" rowspan="1" colspan="1">17.8%<break/>(33/186)</td><td align="left" valign="top" rowspan="1" colspan="1">42.4%<break/>(14/33)</td><td align="left" valign="top" rowspan="1" colspan="1">7.5%<break/>(14/186)&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Casas Herrera, 2016 <xref rid="R31" ref-type="bibr">31</xref></td><td align="left" valign="top" rowspan="1" colspan="1">PUMA study (PLATINO) four countries South America</td><td align="left" valign="top" rowspan="1" colspan="1">N=1540 (80.8%)<break/>Representative; adults &#8805;40 years<break/>Ever-smoker and/or biomass exposure<break/>57 urban/rural centres</td><td align="left" valign="top" rowspan="1" colspan="1">49.7% male 18.8% 40&#8211;49<break/>33.8% 50&#8211;59<break/>47.4% 60+ yrs</td><td align="left" valign="top" rowspan="1" colspan="1">20.1%<break/>(309/1540)</td><td align="left" valign="top" rowspan="1" colspan="1">77.0%<break/>(238/309)&#167;<break/>(range: 63%&#8211;90%)</td><td align="left" valign="top" rowspan="1" colspan="1">15.5%<break/>(238/1540) &#167;<break/>(range: 10%&#8211;23%)</td><td align="left" valign="top" rowspan="1" colspan="1">30.4%<break/>(31/102)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Llord&#233;s, 2015<xref rid="R33" ref-type="bibr">33</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Spain</td><td align="left" valign="top" rowspan="1" colspan="1">N=1738 (70.5%)<break/>Adults &gt;45 years, smoking history on medical records; one primary care centre</td><td align="left" valign="top" rowspan="1" colspan="1">84.3% male<break/>59.9 (10) years</td><td align="left" valign="top" rowspan="1" colspan="1">24.3% (422/1738)<break/>(95% CI 22 to 26)</td><td align="left" valign="top" rowspan="1" colspan="1">56.6%<break/>(239/422)</td><td align="left" valign="top" rowspan="1" colspan="1">13.8% (239/1738)&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">15.7%<break/>(34/217)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Queiroz, 2012<xref rid="R36" ref-type="bibr">36</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Brazil</td><td align="left" valign="top" rowspan="1" colspan="1">N=200 (80%)<break/>Adults &#8805;40 years<break/>&#8805;20 pack-years or &#8805;80 hour-year biomass smoke exposure; 39 urban practices</td><td align="left" valign="top" rowspan="1" colspan="1">60% male<break/>65.9 (11) years</td><td align="left" valign="top" rowspan="1" colspan="1">31.5%<break/>(63/200)</td><td align="left" valign="top" rowspan="1" colspan="1">71.4%<break/>(45/63)</td><td align="left" valign="top" rowspan="1" colspan="1">22.5%<break/>(45/200)&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Al Ghobain, 2011<xref rid="R38" ref-type="bibr">38</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Saudi Arabia</td><td align="left" valign="top" rowspan="1" colspan="1">N=501 (36.3%)<break/>Non-consecutive; adults &#8805;40 years old<break/>Ever-smokers &gt;5 years duration without prior lung disease; 60 private PC clinics</td><td align="left" valign="top" rowspan="1" colspan="1">89.6% male<break/>47.9 (6.9) years</td><td align="left" valign="top" rowspan="1" colspan="1">14.2%<break/>(71/501)</td><td align="left" valign="top" rowspan="1" colspan="1">**</td><td align="left" valign="top" rowspan="1" colspan="1">14.2%<break/>(71/501)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hill <italic toggle="yes">et al</italic><xref rid="R42" ref-type="bibr">42</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Ontario CAN</td><td align="left" valign="top" rowspan="1" colspan="1">N=1003 (15.3%)<break/>Consecutive<break/>Adults &gt;40 years &#8805;20 pack-years<break/>3 GP practices (urban/rural)</td><td align="left" valign="top" rowspan="1" colspan="1">No COPD: 52.6% male, 59 (11) years; COPD: 49.5% male,<break/>65 (9) years</td><td align="left" valign="top" rowspan="1" colspan="1">20.7% (208/1003)</td><td align="left" valign="top" rowspan="1" colspan="1">67.3%<break/>138/205)&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">13.8%<break/>(138/1003)&#182;</td><td align="left" valign="top" rowspan="1" colspan="1">43.7%<break/>(45/103)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Tinkelman, 2007<xref rid="R45" ref-type="bibr">45</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Aberdeen UK, Denver, USA</td><td align="left" valign="top" rowspan="1" colspan="1">N=818 (6%&#8211;24%)&#8225;<break/>Representative; adults &gt;40 years, current or past smokers, no prior OLDs, heart disease or inhaler use<break/>Query no of practices</td><td align="left" valign="top" rowspan="1" colspan="1">49.3% male 58.2 (11) years</td><td align="left" valign="top" rowspan="1" colspan="1">18.9%<break/>(155/818)</td><td align="left" valign="top" rowspan="1" colspan="1">&#182;**</td><td align="left" valign="top" rowspan="1" colspan="1">18.9%<break/>(155/818)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="8">Asthma-COPD registry</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Melbye, 2011<xref rid="R39" ref-type="bibr">39</xref></td><td align="left" valign="top" rowspan="1" colspan="1">DIOLUP, Norway</td><td align="left" valign="top" rowspan="1" colspan="1">N=376 (21.1%)<break/>Adults &#8805;40 years registered with a diagnosis of asthma and/or COPD from 7 practices; latest diagnosis used</td><td align="left" valign="top" rowspan="1" colspan="1">38.0% male<break/>62 years (median)</td><td align="left" valign="top" rowspan="1" colspan="1">39.6% (149/376)<break/>(COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">36.2%<break/>(54/149)&#182; (COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">14.3%<break/>(54/376)&#182;<break/>(COPD only)</td><td align="left" valign="top" rowspan="1" colspan="1">25.8%<break/>(33/128)&#182;<break/>(COPD only)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="8">Medium-high COPD-risk</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Dirven, 2010<xref rid="R41" ref-type="bibr">41</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="left" valign="top" rowspan="1" colspan="1">n=147 (11.7%) undergoing spirometry&#8224;<break/>Adults 40&#8211;75 years without prior OLD at medium-to-high risk for COPD on screening survey; 1 GP at rural practices</td><td align="left" valign="top" rowspan="1" colspan="1">48.7% male<break/>55.2 (9.2) years</td><td align="left" valign="top" rowspan="1" colspan="1">24.5%<break/>(37/147)&#8224;&#8224;</td><td align="left" valign="top" rowspan="1" colspan="1">&#182;**</td><td align="left" valign="top" rowspan="1" colspan="1">24.5%<break/>(37/147)&#8224;&#8224;</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p>*Spirometry-defined COPD based on postbronchodilator spirometry.</p></fn><fn id="T2_FN2"><p>&#8224;COPD prevalence could be inaccurate due to insufficient sample size (<xref rid="SP1" ref-type="supplementary-material">online supplemental results E4</xref>), so have been omitted from the forest plots in a sensitivity analysis.</p></fn><fn id="T2_FN3"><p>&#8225;All % eligible figures were calculated, except when mentioned in the discussion text by Tinkelman <italic toggle="yes">et al</italic>.<xref rid="R48" ref-type="bibr">48</xref></p></fn><fn id="T2_FN4"><p>&#167;COPD was defined using the GOLD criterion, postbronchodilator forced expiratory ratio &lt;0.70; the LLN was also reported by Casas Herrera <italic toggle="yes">et al</italic><xref rid="R31" ref-type="bibr">31</xref> (data not shown).</p></fn><fn id="T2_FN5"><p>&#182;Data needed to be deduced and calculated from the figures given (by the present authors).</p></fn><fn id="T2_FN6"><p>**Percentage undiagnosed in the COPD subpopulation was 100% as the population excluded patients with a history of COPD (3 of total of 7 studies).</p></fn><fn id="T2_FN7"><p>&#8224;&#8224;Data from the manuscript did not quite add up to the percentages given.<xref rid="R31" ref-type="bibr">31 45</xref></p></fn><fn id="T2_FN8"><p>ACO, asthma-COPD overlap; BDR, bronchodilator response; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner; LLN, lower limit of normal; LRTI, lower respiratory tract infection; NA, not available; OLDs, obstructive lung diseases; PC, primary care.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>COPD* and its potential overdiagnosis using postbronchodilator spirometry: COPD case series in primary healthcare settings</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Author year<break/>Citation</td><td align="left" valign="bottom" rowspan="1" colspan="1">Study name location</td><td align="left" valign="bottom" rowspan="1" colspan="1">Participant<break/>no&#8224; (%eligible) &#8225;, Selection, no/type of GP practices</td><td align="left" valign="bottom" rowspan="1" colspan="1">Gender<break/>Age<break/>(mean (SD) years)</td><td align="left" valign="bottom" rowspan="1" colspan="1">COPD cases (COPD&#177;ACO)</td><td align="left" valign="bottom" rowspan="1" colspan="1">Prevalence of spirometry-defined COPD (%, (n/N))&#167;</td><td align="left" valign="bottom" rowspan="1" colspan="1">Overdiagnosis in those labelled with COPD (%, (n/N))&#167;</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Fisk <italic toggle="yes">et al</italic>, 2019<xref rid="R50" ref-type="bibr">50</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Welsh COPD Primary Care Audit, UK</td><td align="left" valign="top" rowspan="1" colspan="1">N=8957 (18.6%)<break/>Patients on the QOF COPD register used by 280 (61%) of 462 Welsh GP practices who had post-BD FEV<sub>1</sub>/FVC read-coded*</td><td align="left" valign="top" rowspan="1" colspan="1">54% male<break/>72 (12) years range 36&#8211;105</td><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="left" valign="top" rowspan="1" colspan="1">74.8%<break/>(6702/8957)</td><td align="left" valign="top" rowspan="1" colspan="1">25.2%<break/>(2255/8957)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ghattas <italic toggle="yes">et al</italic>, 2013<xref rid="R51" ref-type="bibr">51</xref></td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">N=80&#8224;<break/>Consecutive patients either with COPD or clinically managed for COPD symptoms; Single health centre</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.0% male<break/>52.9 (7.7) years</td><td align="left" valign="top" rowspan="1" colspan="1">COPD and ACO</td><td align="left" valign="top" rowspan="1" colspan="1">35.0%<break/>(28/80)</td><td align="left" valign="top" rowspan="1" colspan="1">65.0%<break/>(52/80)&#182;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Walters <italic toggle="yes">et al</italic> 2011<xref rid="R52" ref-type="bibr">52</xref></td><td align="left" valign="top" rowspan="1" colspan="1">TAS, Australia</td><td align="left" valign="top" rowspan="1" colspan="1">N=341 (28%)<break/>Non-consecutive adult patient 40&#8211;80 years managed for COPD with &gt;10 pack-years and &#8805;1 GP visit last 12 months; from 31 urban/rural practices</td><td align="left" valign="top" rowspan="1" colspan="1">48.8% male<break/>Non-COPD 59 (9) COPD 64 (8) years</td><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="left" valign="top" rowspan="1" colspan="1">68.6% (234/341)</td><td align="left" valign="top" rowspan="1" colspan="1">31.4% (107/341)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zwar <italic toggle="yes">et al</italic> 2011<xref rid="R53" ref-type="bibr">53</xref></td><td align="left" valign="top" rowspan="1" colspan="1">PELICAN study, NSW Australia (prior to randomisation)</td><td align="left" valign="top" rowspan="1" colspan="1">N=445 (38.9%)<break/>Non-consecutive adults 40&#8211;80 years clinically managed for COPD; 56 GPs from 44 practices</td><td align="left" valign="top" rowspan="1" colspan="1">No COPD:<break/>44% males; 62 (11)<break/>COPD&#177;asthma:<break/>52% males; 67 (10)</td><td align="left" valign="top" rowspan="1" colspan="1">COPD and ACO</td><td align="left" valign="top" rowspan="1" colspan="1">57.8% (257/445)</td><td align="left" valign="top" rowspan="1" colspan="1">42.2% (188/445)&#182;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sichletidis <italic toggle="yes">et al</italic>, 2007<xref rid="R54" ref-type="bibr">54</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Northern Greece</td><td align="left" valign="top" rowspan="1" colspan="1">N=319 (87.4%)<break/>Non-consecutive adult patients &gt;40 years treated with a COPD diagnosis; 8 health centres</td><td align="left" valign="top" rowspan="1" colspan="1">Symptomatic COPD cases 83.8% male<break/>Age-N/A</td><td align="left" valign="top" rowspan="1" colspan="1">COPD and ACO (n=5)</td><td align="left" valign="top" rowspan="1" colspan="1">50.1% (160/319)</td><td align="left" valign="top" rowspan="1" colspan="1">49.9% (159/319)</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p>*COPD as defined by post-BD airflow obstruction on spirometry testing.</p></fn><fn id="T3_FN2"><p>&#8224;COPD prevalence could be inaccurate due to insufficient sample size (<xref rid="SP1" ref-type="supplementary-material">online supplemental results E4</xref>), so study has been omitted from the forest plot in a sensitivity analysis.</p></fn><fn id="T3_FN3"><p>&#8225;All % eligible figures were calculated.</p></fn><fn id="T3_FN4"><p>&#167;COPD was defined by airflow obstruction detected by postbronchodilator spirometry using the GOLD criterion (forced expiratory ratio &lt;0.70)</p></fn><fn id="T3_FN5"><p>&#182;Data needed to be deduced and calculated from the figures given (by the present authors).</p></fn><fn id="T3_FN6"><p>ACO, asthma-COPD overlap; BD, bronchodilator; COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner; QOF, quality and outcomes framework.</p></fn></table-wrap-foot></table-wrap><sec id="s3-1"><title>Description of studies</title><sec id="s3-1-1"><title>Study origin</title><p>Of 21 cross-sectional prevalence studies, 10 were from Europe/UK,<xref rid="R19" ref-type="bibr">19 30 33 34 37 39&#8211;41 44 46</xref> 3 from South America,<xref rid="R31" ref-type="bibr">31 36 47</xref> 2 from Australia,<xref rid="R29" ref-type="bibr">29 35</xref> 2 from Asia,<xref rid="R32" ref-type="bibr">32 38</xref> 2 from North America,<xref rid="R42" ref-type="bibr">42 43</xref> and 2 from Scotland and the USA<xref rid="R45" ref-type="bibr">45 48</xref> (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S1</xref>). Of five COPD case series, two were from Europe/UK,<xref rid="R50" ref-type="bibr">50 54</xref> two from Australia<xref rid="R52" ref-type="bibr">52 53</xref> and one from the USA.<xref rid="R51" ref-type="bibr">51</xref></p></sec><sec id="s3-1-2"><title>Ages of participants</title><p>Almost all studies recruited adults aged &#8805;40 years (N=23), with an averaged mean study age of 59.1 years (95% CI 47.9 to 68.5, range 46.8&#8211;72 years).</p></sec><sec id="s3-1-3"><title>Diagnostic criteria</title><p>All studies used the GOLD criterion for post-BD spirometry to define COPD (ie, FEV<sub>1</sub>/FVC&lt;0.7), except one cross-sectional study from Poland which used the FEV<sub>1</sub>/FVC&lt;LLN criterion.<xref rid="R44" ref-type="bibr">44</xref> The source of doctor diagnosis for symptomatic patients and COPD case series/registries was health records. This contrasts with patient-reported diagnoses in studies of smokers (irrespective of symptoms), and mixed reporting for other risk categories. This and the adequacy of the sample size are summarised in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure S2</xref>.</p></sec></sec><sec id="s3-2"><title>COPD underdiagnosis</title><sec id="s3-2-1"><title>Absolute proportion of undiagnosed COPD within the total population sample</title><p>The baseline prevalence of spirometry-defined COPD in all cross-sectional studies (N=21) was variable (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S3</xref>). The proportion of spirometry-defined COPD that was undiagnosed in these population samples substantially varied by risk category (I<sup>2</sup>=97.1%, <xref rid="F2" ref-type="fig">figure 2</xref>). For three adequately sized studies of symptomatic smokers, 14%&#8211;26% of these patients had spirometry-confirmed COPD which was not documented in their health records, that is, they had clinical COPD defined by post-BD airflow obstruction and symptom(s)&#177;risk factor(s).<xref rid="R20" ref-type="bibr">20</xref> This was especially more for smokers who had only a clinician diagnosis of chronic bronchitis (25.6%, 95% CI 23.2% to 28.1%), that is, a concurrent COPD diagnosis was not documented in a quarter of medical records.<xref rid="R43" ref-type="bibr">43</xref> Furthermore, undiagnosed COPD was seen for 27.5% of smokers who were treated for a recent lower respiratory tract infection (95% CI 20.7 to 35.5, n=38/138), although this study was excluded from the forest plot in the sensitivity analysis given the small sample size.<xref rid="R40" ref-type="bibr">40</xref> Notably, 14.2% (95% CI 11.5% to 15.7%) of subjects in one Australian study had their COPD undiagnosed, despite attending a PHC clinic at least twice within the last 12 months.<xref rid="R29" ref-type="bibr">29</xref></p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Undiagnosed patients with postbronchodilator airflow obstruction in the total population studied (ES) relating to cross-sectional prevalence studies of sufficient sample size, grouped by risk categories. A pooled estimate was only reported in the main text if the degree of heterogeneity (I<sup>2</sup>) was &lt;75% or if the 95% CIs of all studies within a risk category clearly overlapped. Undiagnosed clinical COPD could be confirmed in the subgroups of symptomatic persons (ie, smokers with symptoms or with symptoms/risk factors) and registries, and these patients did not have a diagnosis of COPD listed in their primary healthcare record. The abbreviation of &#8216;N&#8217; refers to the total number of participants in the study. COPD, chronic obstructive pulmonary disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjresp-2022-001478f02.jpg"/></fig><p>For studies of smokers who had spirometric evidence of COPD (irrespective of symptoms) but did not report receiving a diagnosis, the pooled prevalence estimate was 16% (95% CI 14% to 18%, I<sup>2</sup>=73.5%, <xref rid="F2" ref-type="fig">figure 2</xref>). This contrasted with studies of patients taking inhaled therapies for obstructive lung diseases in which COPD and/or fixed airflow obstruction in people with asthma was undiagnosed in 25% (95% CI 22% to 28%, I<sup>2</sup>=n/a, <xref rid="F2" ref-type="fig">figure 2</xref>).</p></sec><sec id="s3-2-2"><title>Relative proportion underdiagnosed among only those with spirometric evidence of COPD</title><p>Compared with general populations of adults &gt;40 years, overtly at-risk populations with a higher prevalence of COPD confirmed by the researchers&#8217; post-BD spirometry (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S3</xref>) generally had a lower proportion of subjects who were underdiagnosed (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S4</xref> and associated text). Even so, more than half of the symptomatic adults shown to have spirometry-confirmed COPD in these studies did not have the diagnosis entered in their health records, that is, 52%&#8211;63% were underdiagnosed despite having symptoms, and 37%&#8211;48% were formally diagnosed.<xref rid="R29" ref-type="bibr">29 46</xref> Over one-third of Norwegian subjects listed on an asthma-COPD registry who were found to have post-BD airflow obstruction by researchers did not have a current clinician diagnosis of COPD (36.2%).<xref rid="R39" ref-type="bibr">39</xref></p><p>Of these studies, seven reported quantitative data on participant characteristics of patients undiagnosed compared with those doctor diagnosed (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S2</xref>). Having fewer respiratory symptoms,<xref rid="R29" ref-type="bibr">29 30 36 37 42</xref> as well as milder disease (ie, better FEV<sub>1</sub>/FVC),<xref rid="R29" ref-type="bibr">29 31</xref> were consistent features for underdiagnosis. Predisposing features also included younger age,<xref rid="R29" ref-type="bibr">29 30 37</xref> fewer pack-years,<xref rid="R37" ref-type="bibr">37</xref> but paradoxically, also those currently smoking.<xref rid="R29" ref-type="bibr">29 30</xref></p></sec></sec><sec id="s3-3"><title>COPD &#8216;overdiagnosis&#8217;</title><sec id="s3-3-1"><title>Prevalence of absent post-BD airflow obstruction among those labelled with COPD</title><p>From eight heterogeneous cross-sectional studies of adequate sample size, six reported 26%&#8211;52% of patients did not have post-BD airflow obstruction on spirometry, despite probable intent to manage for COPD (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure S5</xref>). The other two individual studies included one Spanish study which had a predominance of male smokers (84%) and reported the lowest proportion &#8216;overdiagnosed&#8217; (15.7%).<xref rid="R33" ref-type="bibr">33</xref> The other was an Austrian general adult population study which considered patient self-reported chronic bronchitis/emphysema as COPD. It adopted a stricter spirometric cut-off criterion (GOLD stage II with FEV<sub>1</sub>&lt;80%<xref rid="R20" ref-type="bibr">20</xref> which could explain why it reported the highest proportion &#8216;overdiagnosed&#8217; (77%).<xref rid="R34" ref-type="bibr">34</xref></p><p>The baseline prevalence of spirometry-confirmed COPD among the adequately powered COPD case series varied between 50% and 75%.<xref rid="R50" ref-type="bibr">50 52&#8211;54</xref> Therefore, 25%&#8211;50% of these patients had no evidence of airflow obstruction on post-BD spirometry and would be considered &#8216;overdiagnosed&#8217; (<xref rid="T3" ref-type="table">table 3</xref> and <xref rid="SP1" ref-type="supplementary-material">online supplemental figure S6</xref>). Two of the prevalence studies also investigated a trial of 4&#8211;6 weeks of inhaled corticosteroid (ICS)-combination inhalers and documented a normalisation of post-BD airflow obstruction in 16%&#8211;19% of treated patients.<xref rid="R33" ref-type="bibr">33 37</xref></p><p>Quantitative data on predisposing factors for &#8216;overdiagnosis&#8217; (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S3</xref>) suggested such participants had fewer symptoms,<xref rid="R42" ref-type="bibr">42 52</xref> were prescribed less respiratory medication,<xref rid="R48" ref-type="bibr">48</xref> younger<xref rid="R52" ref-type="bibr">52 53</xref> and more obese than those who had post-BD spirometric airflow obstruction.<xref rid="R50" ref-type="bibr">50 52</xref></p></sec></sec><sec id="s3-4"><title>Risk of bias: JBI critical appraisal tools</title><p>All studies used valid identification methods, that is, post-BD spirometry, appropriate definitions and population-specific reference values. However, the overall quality was moderate at best, since 17 of 26 studies did not satisfy at least 1 of the required criteria. Specifically, some cross-sectional prevalence studies (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S4</xref>) had limited sampling frames,<xref rid="R19" ref-type="bibr">19 33 41 44 46</xref> recruited convenience samples,<xref rid="R19" ref-type="bibr">19 30 35 36 43</xref> had low recruitment rates,<xref rid="R29" ref-type="bibr">29 35 42 46 48</xref> an inadequate sample size to accurately estimate COPD prevalence,<xref rid="R30" ref-type="bibr">30 40 41 47</xref> used a combination of microspirometry and spirometry<xref rid="R29" ref-type="bibr">29</xref> or the prevalence figures for COPD underdiagnosis were difficult to find.<xref rid="R19" ref-type="bibr">19 34 41 43</xref> Only one prevalence study provided 95% CIs<xref rid="R33" ref-type="bibr">33</xref>; another reported that most testing staff were not trained.<xref rid="R29" ref-type="bibr">29</xref> Similarly of the five COPD case series (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S5</xref>), three recruited participants in a non-consecutive manner<xref rid="R52" ref-type="bibr">52&#8211;54</xref> and another was underpowered to estimate true COPD prevalence.<xref rid="R51" ref-type="bibr">51</xref> Further details including the sample size estimations are reported in <xref rid="SP1" ref-type="supplementary-material">online supplemental results S4</xref>. None of the studies were excluded from this review based on low quality; however, those with small sample sizes relative to COPD prevalence were part of a sensitivity analysis and were not shown in the illustrative forest plots. Their absence made little difference to the message.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Our systematic review has found that both undiagnosed and &#8216;overdiagnosed&#8217; COPD were common in PHC settings when COPD was defined by post-BD airflow obstruction<xref rid="R20" ref-type="bibr">20</xref> as determined by the study researchers. For the first time, we have reworked the definition of undiagnosed COPD to estimate that 14%&#8211;26% of all symptomatic smokers attending a PHC clinic have spirometry-confirmable COPD which was not documented in their health records. This review also estimates that one in four patients taking inhaled therapies have fixed obstructive lung function consistent with COPD that was not formally documented by the treating clinician<xref rid="R35" ref-type="bibr">35</xref> and/or recognised by the patient.<xref rid="R48" ref-type="bibr">48</xref> While knowledge of the relative prevalence of undiagnosed COPD is difficult to translate to a clinical context, we estimated that less than half of symptomatic adults who had spirometry-confirmable COPD had this diagnosis entered into their medical records.</p><p>In contrast, around 25%&#8211;50% of people labelled or managed as having COPD had no airflow obstruction on spirometry when tested by study researchers, which has been described by the field as COPD &#8216;overdiagnosis&#8217;. Quotation marks were used as spirometry is relatively insensitive at detecting COPD in its early stages,<xref rid="R55" ref-type="bibr">55</xref> so it is possible that some patients taking corticosteroid (ICS)-combination inhalers could have been treated for chronic airflow limitation at this potentially reversible stage<xref rid="R33" ref-type="bibr">33 37 56</xref> and this needs testing in prospective trials. Although the studies included in this review were limited, heterogeneous and variable in quality, the findings raise important issues around the accuracy of COPD diagnosis in PHC settings.</p><sec id="s4-1"><title>Undiagnosed COPD is common in at-risk populations</title><p>In this review, we have shown that many symptomatic smokers who had attended their PHC clinic even multiple times within the last 12 months,<xref rid="R29" ref-type="bibr">29</xref> had spirometry-confirmable COPD that was not documented by their treating clinician. However, the exact reasons for their attendances and whether they were treated with inhaled therapies were not specified. In another small study, a quarter of smokers treated for a recent lower respiratory tract infection had undiagnosed COPD,<xref rid="R40" ref-type="bibr">40</xref> and we note some major guidelines suggest that recurrent infections should raise clinical suspicion for COPD.<xref rid="R3" ref-type="bibr">3 4</xref></p><p>While under-reporting can occur if individuals normalise their symptoms as simply a &#8216;smokers&#8217; cough&#8217; or &#8216;old age&#8217;,<xref rid="R57" ref-type="bibr">57</xref> our findings likely reflect an underinterrogation and/or investigation of COPD by clinicians for this high-risk group. It is possible that many primary care clinicians are unaware that adults with undiagnosed COPD are at much higher risk for acute exacerbations, pneumonia or death, even if they are asymptomatic.<xref rid="R58" ref-type="bibr">58</xref> Confirmation of a COPD diagnosis with spirometry has been associated with fewer hospital admissions and reduced COPD-related mortality,<xref rid="R59" ref-type="bibr">59</xref> most likely because of more appropriate clinical management. Importantly, we highlight at-risk groups of patients in PHC for whom COPD is commonly unrecognised and an accurate diagnosis might well improve health outcomes.</p><p>Internationally recognised experts,<xref rid="R60" ref-type="bibr">60</xref> expert bodies<xref rid="R61" ref-type="bibr">61 62</xref> and guidelines<xref rid="R4" ref-type="bibr">4&#8211;7 20</xref> advocate for active COPD case-finding by objectively testing high-risk groups. While systematic case-finding by inviting smokers to undergo serial spirometry has potential to be cost-effective,<xref rid="R63" ref-type="bibr">63 64</xref> in practice, clinicians tend not to record patients with less severe symptoms/disease within a COPD registry<xref rid="R65" ref-type="bibr">65</xref> which would facilitate best practice care.</p></sec><sec id="s4-2"><title>COPD &#8216;overdiagnosis&#8217; is a complex issue</title><p>Several studies and quality improvement activities from PHC settings in both high-income<xref rid="R66" ref-type="bibr">66&#8211;68</xref> and low-income and middle-income countries (LMICs)<xref rid="R69" ref-type="bibr">69</xref> have shown that fewer than 40% of patients labelled as having COPD had had their diagnosis confirmed objectively by spirometry, that is, with likely substantial overdiagnosis. This is consistent with large numbers of patients being prescribed respiratory medicines including BD on a presumption that they have COPD.<xref rid="R70" ref-type="bibr">70</xref> Interestingly, a large randomised controlled trial of symptomatic smokers with no airflow obstruction on spirometry found symptoms were improved similarly in both treatment and placebo arms (56.4% improved following 12 weeks of dual BD therapy compared with 59.0% taking a placebo).<xref rid="R71" ref-type="bibr">71</xref> This suggests that symptoms can vary over time,<xref rid="R55" ref-type="bibr">55</xref> and this treatment itself has limited efficacy for such patients.</p><p>Given the potential for diagnostic confusion, clinicians may undertreat other medical conditions such as asthma, heart failure<xref rid="R72" ref-type="bibr">72</xref> and/or bronchiectasis. Symptoms such as wheezing, breathlessness and cough/sputum are non-specific and overlap with those of COPD. This is also the case for people who are obese and present with breathlessness on exertion.<xref rid="R50" ref-type="bibr">50 52</xref> While we cannot elucidate the true reasons why the studied patients may have been &#8216;overdiagnosed&#8217;, this systematic review has highlighted issues of empirically treating early COPD and the potential for inappropriate prescribing of medicines.</p></sec><sec id="s4-3"><title>Underutilisation of objective testing: a global problem</title><p>A central issue to both COPD underdiagnosis and overdiagnosis<xref rid="R35" ref-type="bibr">35 45 46 52 53</xref> is the underuse of objective testing,<xref rid="R20" ref-type="bibr">20</xref> when spirometry performed well is diagnostic, reliable and non-invasive. However, even in the pre-COVID-19 era, access to this point-of-care test was limited in many PHC settings for multiple reasons. These included a lack of testing expertise and training, time allocation and/or low financial incentives. In addition, uncertainty in interpreting spirometry can be a major barrier to best practice.<xref rid="R73" ref-type="bibr">73</xref> In these situations, establishing an accurate diagnosis, therefore, currently relies on the availability of laboratory-based spirometry, but long waiting lists, out-of-pocket expenses and excessive travel time/distances are often barriers. This is especially so in LMICs.<xref rid="R74" ref-type="bibr">74</xref></p><p>Potential facilitators of improved guideline adherence could include professional development for doctors and practice nurses, integrating lung function testing reminders into electronic health records and/or developing decision support technology and algorithms to increase awareness and instil confidence in clinicians to test and more accurately assess patients.<xref rid="R75" ref-type="bibr">75</xref> However, these initiatives would only partly address the additional clinician-based factors of: over-reliance and/or &#8216;overconfidence&#8217; in clinical-only diagnostic skills<xref rid="R76" ref-type="bibr">76</xref>; mislabelling in hospital discharge summaries being carried forward into a PHC diagnosis; and frequently an attitude of nihilism<xref rid="R73" ref-type="bibr">73</xref> and viewing the spirometer as a means of convincing the patient to stop smoking rather than a tool to aid accurate diagnosis.<xref rid="R35" ref-type="bibr">35</xref></p><p>While local diagnostic protocols may differ between geographical regions, PHC services and stages of the SARS-CoV-2 pandemic<xref rid="R77" ref-type="bibr">77</xref> a detailed discussion of these protocols is beyond the scope of this review but is unlikely to change the clinical picture presented. However, we note that all studies included in this review were from the pre-COVID-19 era. During the pandemic, the number of primary care spirometry tests in particular fell dramatically from prolonged disruptions that has now led to the deskilling of staff with probable loss of confidence in performing spirometry. This has only been partially reversed in the &#8216;living-with-COVID-19&#8217; era<xref rid="R78" ref-type="bibr">78</xref> due to ongoing concerns about the potential spread of SARS-CoV-2 virus to healthcare workers and patients through performing spirometry which can generate aerosol droplets, especially by inducing coughing.<xref rid="R79" ref-type="bibr">79 80</xref></p><p>Professional societies have provided evidence-based protocols of infection prevention control for spirometry testing at the point of care in PHC settings that include adequate ventilation in testing spaces, cleaning of room and equipment, single-use in-line antimicrobial filters and full personal protective equipment.<xref rid="R79" ref-type="bibr">79&#8211;83</xref> Complying with the ventilatory requirements can be particularly difficult as most practices do not have the resources or expertise to estimate the adequacy of ventilation provided, and rooms may need to be reconfigured or else vacated for a period between testing patients. Together with staff re-engagement and retraining, the costs associated with these COVID-19 safe protocols can be prohibitive in PHC services. This poses a serious new challenge for primary care clinicians when trying to follow clinical pathways that align with the recommendations of COPD guidelines,<xref rid="R4" ref-type="bibr">4&#8211;7 20</xref> given that access to public and private respiratory laboratories can be limited by either availability or patient out-of-pocket expenses, respectively. A potential way forward is developing prediction tools that risk-stratify patients,<xref rid="R8" ref-type="bibr">8 84</xref> and/or establishing diagnostic &#8216;hubs or hublets&#8217; to provide a good-quality diagnostic spirometry service at a local network level in the community.<xref rid="R81" ref-type="bibr">81 85</xref></p></sec><sec id="s4-4"><title>Strengths and limitations</title><p>This first systematic review has intentionally studied &#8216;real-world&#8217; PHC clinic samples, employing a widely accepted objective diagnostic criterion for confirming a COPD diagnosis,<xref rid="R20" ref-type="bibr">20</xref> while minimising the confounding potential of predominant asthma if only pre-BD spirometry was assessed.</p><p>We acknowledge that excluding articles published only in languages other than English at the title/abstract phase may have missed some evidence and could have limited the generalisability of findings. We also could not directly assess the included studies for publication bias, as there is no well-accepted equivalent of a funnel or Egger&#8217;s plot for prevalence studies. However, our sample size calculations confirmed that approximately one-fifth of studies (n=5) had been published despite low subject numbers.<xref rid="R26" ref-type="bibr">26 27</xref></p><p>The risk of bias was at least moderate, with substantial heterogeneity between included studies such that pooled estimates were uncommonly reported. In all but two studies,<xref rid="R19" ref-type="bibr">19 31</xref> the age spectrum of COPD was not considered, despite COPD being more common in the elderly. There were only limited studies from Asia and none from Africa, so the findings should not be generalised to these continents and more research is needed there.</p></sec></sec><sec id="s5"><title>Summary</title><p>In this systematic review, we have estimated the absolute proportions of undiagnosed spirometry-confirmed COPD (ie, symptomatic patients who were not documented by primary care clinicians to have COPD but had post-BD airflow obstruction when studied) and thus the potential extent of disease undermanagement in PHC patient populations based on their underlying risk profiles. Furthermore, this review has revealed that many patients who do not have spirometric evidence of COPD when studied have a clinical label of COPD in their health record. Other than a lack of spirometry to confirm or refute a COPD diagnosis accurately, potential explanations also include clinicians not accurately documenting patient diagnoses in the PHC health record, patients not recalling receiving their COPD diagnosis accurately, and patients being already treated prior to spirometry.</p><p>Nonetheless, this review highlights that underdiagnosis and overdiagnosis of COPD is a complex and multifaceted problem, and the magnitude of this issue is expected to worsen given even further reductions in spirometry use post-COVID-19. There is an underlying need for greater awareness and action by both at-risk patients and healthcare providers about reporting and documenting symptoms and then objectively investigating for a potential COPD diagnosis. However, more robust scientific and economic evidence of benefit of earlier diagnosis is also needed for public health systems to increase funding and support that might improve the culture of active case-finding for COPD and enhance use of spirometry in PHC settings.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> JP, KH, EHW and MJA conceptualised the study. SWSY mapped the literature then JP/EHW designed the study. Overseen by NW and JP registered the protocol, SWSY/JP reviewed titles/abstracts, SWSY/NSI reviewed full texts and SWSY/JP extracted the full data. JP performed the data analysis and led the interpretation, supervised by SCD and NW. JP drafted the manuscript which was revised by SWSY/EHW and critically assessed for important intellectual content by all authors. JP revised the manuscript after peer review with input from all authors, especially KH. All authors approved the final version. JP submitted the study and has taken responsibility for the overall content as guarantor.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> JP and SCD were supported by the NHRMC of Australia APP1159090 and APP1193993 respectively.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> JP, SCD, EHW and MJA hold an investigator-initiated grant from GlaxoSmithKline for unrelated research, and SCD and JP have an investigator-initiated partnership grant with AstraZeneca for unrelated research. MJA additionally holds investigator-initiated grants from Pfizer, Boehringer-Ingelheim and Sanofi for unrelated research; has undertaken an unrelated consultancy for Sanofi; and received a speaker&#8217;s fee from GlaxoSmithKline. KH has received personal fees and non-financial support from Astra Zeneca, GlaxoSmithKline, Novartis, Chiesi, Boehringer Ingelheim and Teva outside the submitted work. KH has also received fees for performing spirometry and for training health professionals in spirometry testing.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn></fn-group><sec sec-type="data-availability"><title>Data availability statement</title><p>All data relevant to the present systematic review/meta-analysis are included in the article or uploaded as online supplemental information.</p></sec><sec sec-type="ethics-statement"><title>Ethics statements</title><sec><title>Patient consent for publication</title><p content-type="ethics-consent-to-publish">Not applicable.</p></sec><sec><title>Ethics approval</title><p content-type="ethics-approval">As this systematic review analysed publicly available, aggregated, and non-identifiable patient data, this study did not require ethical approval as there was no risk to participants.</p></sec></sec><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <article-title>The top 10 causes of death. Fact sheet</article-title>. <year>2020</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death">https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death</uri> [Accessed <comment>3 Apr 2021</comment>].</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Young</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Hopkins</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Christmas</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Copd prevalence is increased in lung cancer, independent of age, sex and smoking history</article-title>. <source>Eur Respir J</source><year>2009</year>;<volume>34</volume>:<fpage>380</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00144208</pub-id><pub-id pub-id-type="pmid">19196816</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group>. <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease</article-title>. <year>2023</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://goldcopd.org/2023-gold-report-2">https://goldcopd.org/2023-gold-report-2</uri> [Accessed <comment>23 Jan 2023</comment>].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>NICE</collab></person-group>. <source>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</source>. <publisher-loc>London</publisher-loc>, <year>2019</year>.<pub-id pub-id-type="pmid">31211541</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Dabscheck</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <source>The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. version 2</source>. <publisher-name>Lung Foundation Australia</publisher-name>, <year>2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://copdx.org.au/wp-content/uploads/2021/04/COPDX-V2-63-Feb-2021_FINAL-PUBLISHED.pdf">https://copdx.org.au/wp-content/uploads/2021/04/COPDX-V2-63-Feb-2021_FINAL-PUBLISHED.pdf</uri></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Chronic Obstructive Pulmonary Disease (COPD)</collab></person-group>. <article-title>Diagnosis and management. Effective</article-title>. <year>2017</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/copd_full_guideline.pdf">https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/copd_full_guideline.pdf</uri> [Accessed <comment>24 Jan 2023</comment>].</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Rhee</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Yoon</surname><given-names>HK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Revised (2018) COPD clinical practice guideline of the Korean academy of tuberculosis and respiratory disease: A summary</article-title>. <source>Tuberc Respir Dis (Seoul)</source><year>2018</year>;<volume>81</volume>:<fpage>261</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.4046/trd.2018.0029</pub-id><pub-id pub-id-type="pmid">29926554</pub-id><pub-id pub-id-type="pmcid">PMC6148094</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stolz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mkorombindo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schumann</surname><given-names>DM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Towards the elimination of chronic obstructive pulmonary disease: a lancet commission</article-title>. <source>Lancet</source><year>2022</year>;<volume>400</volume>:<fpage>921</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(22)01273-9</pub-id><pub-id pub-id-type="pmid">36075255</pub-id><pub-id pub-id-type="pmcid">PMC11260396</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Albasri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nicholson</surname><given-names>BD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Overtesting and undertesting in primary care: a systematic review and meta-analysis</article-title>. <source>BMJ Open</source><year>2018</year>;<volume>8</volume>:<elocation-id>e018557</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2017-018557</pub-id><pub-id pub-id-type="pmcid">PMC5829845</pub-id><pub-id pub-id-type="pmid">29440142</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calverley</surname><given-names>PM</given-names></string-name></person-group>. <article-title>COPD: early detection and intervention</article-title>. <source>Chest</source><year>2000</year>;<volume>117</volume>:<fpage>365S</fpage>&#8211;<lpage>71S</lpage>. <pub-id pub-id-type="doi">10.1378/chest.117.5_suppl_2.365s</pub-id><pub-id pub-id-type="pmid">10843978</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hunter</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Butcher</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patient characteristics associated with risk of first hospital admission and readmission for acute exacerbation of chronic obstructive pulmonary disease (COPD) following primary care COPD diagnosis: a cohort study using linked electronic patient records</article-title>. <source>BMJ Open</source><year>2016</year>;<volume>6</volume>:<elocation-id>e009121</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009121</pub-id><pub-id pub-id-type="pmcid">PMC4735181</pub-id><pub-id pub-id-type="pmid">26801463</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Balcells</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ant&#243;</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gea</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Characteristics of patients admitted for the first time for COPD exacerbation</article-title>. <source>Respir Med</source><year>2009</year>;<volume>103</volume>:<fpage>1293</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2009.04.001</pub-id><pub-id pub-id-type="pmid">19427776</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>RCM</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort</article-title>. <source>Lancet Respir Med</source><year>2014</year>;<volume>2</volume>:<fpage>267</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(14)70008-6</pub-id><pub-id pub-id-type="pmid">24717623</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Glasziou</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dobler</surname><given-names>CC</given-names></string-name></person-group>. <article-title>Use of the terms &#8220;overdiagnosis&#8221; and &#8220;misdiagnosis&#8221; in the COPD literature: a rapid review</article-title>. <source>Breathe (Sheff)</source><year>2019</year>;<volume>15</volume>:<fpage>e8</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1183/20734735.0354-2018</pub-id><pub-id pub-id-type="pmid">31031840</pub-id><pub-id pub-id-type="pmcid">PMC6481986</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ho</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cusack</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Under- and over-diagnosis of COPD: a global perspective</article-title>. <source>Breathe (Sheff)</source><year>2019</year>;<volume>15</volume>:<fpage>24</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1183/20734735.0346-2018</pub-id><pub-id pub-id-type="pmid">30838057</pub-id><pub-id pub-id-type="pmcid">PMC6395975</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koblizek</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Novotna</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zbozinkova</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diagnosing COPD: advances in training and practice-a systematic review</article-title>. <source>Adv Med Educ Pract</source><year>2016</year>;<volume>7</volume>:<fpage>219</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2147/AMEP.S76976</pub-id><pub-id pub-id-type="pmid">27099544</pub-id><pub-id pub-id-type="pmcid">PMC4825818</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Diab</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gershon</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Sin</surname><given-names>DD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source><year>2018</year>;<volume>198</volume>:<fpage>1130</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201804-0621CI</pub-id><pub-id pub-id-type="pmid">29979608</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petrie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Toelle</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Wood-Baker</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Undiagnosed and misdiagnosed chronic obstructive pulmonary disease: data from the BOLD Australia study</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source><year>2021</year>;<volume>16</volume>:<fpage>467</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S287172</pub-id><pub-id pub-id-type="pmid">33658776</pub-id><pub-id pub-id-type="pmcid">PMC7920499</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siatkowska</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kozielski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ziora</surname><given-names>D</given-names></string-name></person-group>. <article-title>Chronic obstructive pulmonary disease patients in the general practice</article-title>. <source>Pneumonol Alergol Pol</source><year>2010</year>;<volume>78</volume>:<fpage>112</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.5603/ARM.27736</pub-id><pub-id pub-id-type="pmid">20306422</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease (GOLD)</collab></person-group>. <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease</article-title>. <year>2021</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf">https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf</uri> [Accessed <comment>21 May 2021</comment>].</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Perret</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yip</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Waidyatillake</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chronic obstructive pulmonary disease prevalence and its underdiagnosis and overdiagnosis in primary care settings. PROSPERO 2022 CRD42022295832</article-title>. <year>2022</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022295832">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022295832</uri></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><year>2021</year>;<volume>372</volume>:<elocation-id>n71</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Veritas Health Innovation</collab></person-group>. <article-title>Covidence systematic review software, Melbourne, Australia</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.covidence.org">www.covidence.org</uri></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Munn</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Moola</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lisy</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data</article-title>. <source>Int J Evid Based Healthc</source><year>2015</year>;<volume>13</volume>:<fpage>147</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1097/XEB.0000000000000054</pub-id><pub-id pub-id-type="pmid">26317388</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Munn</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Barker</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Moola</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Methodological quality of case series studies: an introduction to the JBI critical appraisal tool</article-title>. <source>JBI Evid Synth</source><year>2020</year>;<volume>18</volume>:<fpage>2127</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.11124/JBISRIR-D-19-00099</pub-id><pub-id pub-id-type="pmid">33038125</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Daniel</surname><given-names>WW</given-names></string-name></person-group>. <source>Biostatistics: a foundation for analysis in the health sciences</source>. <edition>7th ed</edition>. <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1999</year>.</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pourhoseingholi</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Vahedi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rahimzadeh</surname><given-names>M</given-names></string-name></person-group>. <article-title>Sample size calculation in medical studies</article-title>. <source>Gastroenterol Hepatol Bed Bench</source><year>2013</year>;<volume>6</volume>:<fpage>14</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24834239</pub-id><pub-id pub-id-type="pmcid">PMC4017493</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nyaga</surname><given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>Arbyn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aerts</surname><given-names>M</given-names></string-name></person-group>. <article-title>Metaprop: a stata command to perform meta-analysis of binomial data</article-title>. <source>Arch Public Health</source><year>2014</year>;<volume>72</volume>:<elocation-id>39</elocation-id>. <pub-id pub-id-type="doi">10.1186/2049-3258-72-39</pub-id><pub-id pub-id-type="pmid">25810908</pub-id><pub-id pub-id-type="pmcid">PMC4373114</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Abramson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Zwar</surname><given-names>NA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diagnosing COPD and supporting smoking cessation in general practice: evidence-practice gaps</article-title>. <source>Med J Aust</source><year>2018</year>;<volume>208</volume>:<fpage>29</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.5694/mja17.00664</pub-id><pub-id pub-id-type="pmid">29320670</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stafyla</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kotsiou</surname><given-names>OS</given-names></string-name>, <string-name name-style="western"><surname>Deskata</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Missed diagnosis and overtreatment of COPD among smoking primary care population in central Greece: old problems persist</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source><year>2018</year>;<volume>13</volume>:<fpage>487</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S147628</pub-id><pub-id pub-id-type="pmid">29440886</pub-id><pub-id pub-id-type="pmcid">PMC5804734</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Casas Herrera</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Montes de Oca</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez Varela</surname><given-names>MV</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Copd underdiagnosis and misdiagnosis in a high-risk primary care population in four Latin American countries. A key to enhance disease diagnosis: the PUMA study</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<elocation-id>e0152266</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0152266</pub-id><pub-id pub-id-type="pmid">27073880</pub-id><pub-id pub-id-type="pmcid">PMC4830516</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Utsugi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Associations of lifelong cigarette consumption and hypertension with airflow limitation in primary care clinic outpatients in Japan</article-title>. <source>Respir Investig</source><year>2016</year>;<volume>54</volume>:<fpage>35</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.resinv.2015.08.003</pub-id><pub-id pub-id-type="pmid">26718143</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Llord&#233;s</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ja&#233;n</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Almagro</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence, risk factors and diagnostic accuracy of COPD among smokers in primary care</article-title>. <source>COPD</source><year>2015</year>;<volume>12</volume>:<fpage>404</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3109/15412555.2014.974736</pub-id><pub-id pub-id-type="pmid">25474184</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weiss</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Steinacher</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lamprecht</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Detection of chronic obstructive pulmonary disease in primary care in Salzburg, Austria: findings from the real world</article-title>. <source>Respiration</source><year>2014</year>;<volume>87</volume>:<fpage>136</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1159/000354796</pub-id><pub-id pub-id-type="pmid">24296512</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abramson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Schattner</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Sulaiman</surname><given-names>ND</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Accuracy of asthma and COPD diagnosis in Australian general practice: a mixed methods study</article-title>. <source>Prim Care Respir J</source><year>2012</year>;<volume>21</volume>:<fpage>167</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.4104/pcrj.2011.00103</pub-id><pub-id pub-id-type="pmid">22234387</pub-id><pub-id pub-id-type="pmcid">PMC6547914</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Queiroz</surname><given-names>M de C de</given-names></string-name>, <string-name name-style="western"><surname>Moreira</surname><given-names>MAC</given-names></string-name>, <string-name name-style="western"><surname>Rabahi</surname><given-names>MF</given-names></string-name></person-group>. <article-title>Underdiagnosis of COPD at primary health care clinics in the city of aparecida de Goi&#226;nia, Brazil</article-title>. <source>J Bras Pneumol</source><year>2012</year>;<volume>38</volume>:<fpage>692</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1590/s1806-37132012000600003</pub-id><pub-id pub-id-type="pmid">23288113</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>L&#248;kke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ulrik</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Dahl</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice</article-title>. <source>COPD</source><year>2012</year>;<volume>9</volume>:<fpage>458</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.3109/15412555.2012.685118</pub-id><pub-id pub-id-type="pmid">22643016</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al Ghobain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Al-Hajjaj</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Wali</surname><given-names>SO</given-names></string-name></person-group>. <article-title>Prevalence of chronic obstructive pulmonary disease among smokers attending primary healthcare clinics in Saudi Arabia</article-title>. <source>Ann Saudi Med</source><year>2011</year>;<volume>31</volume>:<fpage>129</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.4103/0256-4947.77485</pub-id><pub-id pub-id-type="pmid">21403413</pub-id><pub-id pub-id-type="pmcid">PMC3102470</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melbye</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Drivenes</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dalbak</surname><given-names>LG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source><year>2011</year>;<volume>6</volume>:<fpage>597</fpage>&#8211;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S25955</pub-id><pub-id pub-id-type="pmid">22135492</pub-id><pub-id pub-id-type="pmcid">PMC3224654</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sandelowsky</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>St&#228;llberg</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nager</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections-a case finding study</article-title>. <source>BMC Fam Pract</source><year>2011</year>;<volume>12</volume>:<elocation-id>122</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-2296-12-122</pub-id><pub-id pub-id-type="pmid">22047519</pub-id><pub-id pub-id-type="pmcid">PMC3228744</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dirven</surname><given-names>JAM</given-names></string-name>, <string-name name-style="western"><surname>Muris</surname><given-names>JWM</given-names></string-name>, <string-name name-style="western"><surname>van Schayck</surname><given-names>CP</given-names></string-name></person-group>. <article-title>Copd screening in general practice using a telephone questionnaire</article-title>. <source>COPD</source><year>2010</year>;<volume>7</volume>:<fpage>352</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3109/15412555.2010.510547</pub-id><pub-id pub-id-type="pmid">20854050</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hill</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Goldstein</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Guyatt</surname><given-names>GH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care</article-title>. <source>CMAJ</source><year>2010</year>;<volume>182</volume>:<fpage>673</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.091784</pub-id><pub-id pub-id-type="pmid">20371646</pub-id><pub-id pub-id-type="pmcid">PMC2855915</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yawn</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mannino</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Littlejohn</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence of COPD among symptomatic patients in a primary care setting</article-title>. <source>Curr Med Res Opin</source><year>2009</year>;<volume>25</volume>:<fpage>2671</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1185/03007990903241350</pub-id><pub-id pub-id-type="pmid">19757984</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bednarek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maciejewski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wozniak</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence, severity and underdiagnosis of COPD in the primary care setting</article-title>. <source>Thorax</source><year>2008</year>;<volume>63</volume>:<fpage>402</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2007.085456</pub-id><pub-id pub-id-type="pmid">18234906</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tinkelman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nordyke</surname><given-names>RJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Copd screening efforts in primary care: what is the yield?</article-title><source>Prim Care Respir J</source><year>2007</year>;<volume>16</volume>:<fpage>41</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3132/pcrj.2007.00009</pub-id><pub-id pub-id-type="pmid">17297526</pub-id><pub-id pub-id-type="pmcid">PMC6634176</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frank</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Hazell</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Linehan</surname><given-names>MF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The diagnostic accuracies of chronic obstructive pulmonary disease (COPD) in general practice: the results of the MAGIC (manchester airways group identifying COPD) study</article-title>. <source>Prim Care Respir J</source><year>2006</year>;<volume>15</volume>:<fpage>286</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcrj.2006.07.007</pub-id><pub-id pub-id-type="pmid">16978921</pub-id><pub-id pub-id-type="pmcid">PMC6730827</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamers</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bontemps</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van den Akker</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chronic obstructive pulmonary disease in brazilian primary care: diagnostic competence and case-finding</article-title>. <source>Prim Care Respir J</source><year>2006</year>;<volume>15</volume>:<fpage>299</fpage>&#8211;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcrj.2006.07.008</pub-id><pub-id pub-id-type="pmid">16978923</pub-id><pub-id pub-id-type="pmcid">PMC6730828</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tinkelman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Nordyke</surname><given-names>RJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over</article-title>. <source>J Asthma</source><year>2006</year>;<volume>43</volume>:<fpage>75</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1080/02770900500448738</pub-id><pub-id pub-id-type="pmid">16448970</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heffler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Crimi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mancuso</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients</article-title>. <source>Respir Med</source><year>2018</year>;<volume>142</volume>:<fpage>48</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2018.07.015</pub-id><pub-id pub-id-type="pmid">30170801</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fisk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McMillan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Inaccurate diagnosis of COPD: the welsh national COPD audit</article-title>. <source>Br J Gen Pract</source><year>2019</year>;<volume>69</volume>:<fpage>e1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3399/bjgp18X700385</pub-id><pub-id pub-id-type="pmid">30559109</pub-id><pub-id pub-id-type="pmcid">PMC6301368</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ghattas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gemmel</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source><year>2013</year>;<volume>8</volume>:<fpage>545</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S45693</pub-id><pub-id pub-id-type="pmid">24348030</pub-id><pub-id pub-id-type="pmcid">PMC3848507</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walters</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Factors associated with misdiagnosis of COPD in primary care</article-title>. <source>Prim Care Respir J</source><year>2011</year>;<volume>20</volume>:<fpage>396</fpage>&#8211;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.4104/pcrj.2011.00039</pub-id><pub-id pub-id-type="pmid">21687918</pub-id><pub-id pub-id-type="pmcid">PMC6549875</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zwar</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Marks</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Hermiz</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice</article-title>. <source>Med J Aust</source><year>2011</year>;<volume>195</volume>:<fpage>168</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.5694/j.1326-5377.2011.tb03271.x</pub-id><pub-id pub-id-type="pmid">21843115</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sichletidis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chloros</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Spyratos</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The validity of the diagnosis of chronic obstructive pulmonary disease in general practice</article-title>. <source>Prim Care Respir J</source><year>2007</year>;<volume>16</volume>:<fpage>82</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3132/pcrj.2007.00016</pub-id><pub-id pub-id-type="pmid">17377688</pub-id><pub-id pub-id-type="pmcid">PMC6634186</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sin</surname><given-names>DD</given-names></string-name></person-group>. <article-title>RETHINCking COPD-bronchodilators for symptomatic tobacco-exposed persons with preserved lung function?</article-title><source>N Engl J Med</source><year>2022</year>;<volume>387</volume>:<fpage>1230</fpage>&#8211;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMe2210347</pub-id><pub-id pub-id-type="pmid">36066080</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global Initiative for Asthma</collab></person-group>. <article-title>Global strategy for asthma management and prevention</article-title>. <year>2022</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.ginasthma.org">www.ginasthma.org</uri> [Accessed <comment>24 Jun 2022</comment>].</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pinnock</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sohanpal</surname><given-names>R</given-names></string-name></person-group>. <article-title>Chronic obstructive pulmonary disease: reduced nihilism, but there is still a ways to go</article-title>. <source>Chronic Obstr Pulm Dis</source><year>2016</year>;<volume>3</volume>:<fpage>605</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.15326/jcopdf.3.3.2016.0151</pub-id><pub-id pub-id-type="pmid">28848886</pub-id><pub-id pub-id-type="pmcid">PMC5556755</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>&#199;olak</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Afzal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nordestgaard</surname><given-names>BG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in denmark: a prospective cohort study</article-title>. <source>Lancet Respir Med</source><year>2017</year>;<volume>5</volume>:<fpage>426</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(17)30119-4</pub-id><pub-id pub-id-type="pmid">28389225</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gershon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mecredy</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Croxford</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing</article-title>. <source>CMAJ</source><year>2017</year>;<volume>189</volume>:<fpage>E530</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.151420</pub-id><pub-id pub-id-type="pmid">28396329</pub-id><pub-id pub-id-type="pmcid">PMC5386846</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Price</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cleland</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Earlier diagnosis and earlier treatment of COPD in primary care</article-title>. <source>Prim Care Respir J</source><year>2011</year>;<volume>20</volume>:<fpage>15</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4104/pcrj.2010.00060</pub-id><pub-id pub-id-type="pmid">20871945</pub-id><pub-id pub-id-type="pmcid">PMC6602161</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Heart, Lung and Blood Institute</collab></person-group>. <article-title>A case-finding strategy for moderate-to-severe COPD in the United States</article-title>. <year>2008</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nhlbi.nih.gov/events/2008/case-finding-strategy-moderate-severe-copd-united-states">https://www.nhlbi.nih.gov/events/2008/case-finding-strategy-moderate-severe-copd-united-states</uri> [Accessed <comment>30 Sep 2019</comment>].</mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Lung Foundation Australia</collab></person-group>. <article-title>Position paper. COPD case finding in community settings</article-title>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://lungfoundation.com.au/wp-content/uploads/2018/11/Information-Paper-COPD-Case-Finding-position-paper-Oct2019.pdf">https://lungfoundation.com.au/wp-content/uploads/2018/11/Information-Paper-COPD-Case-Finding-position-paper-Oct2019.pdf</uri> [Accessed <comment>15 Nov 2019</comment>].</mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jordan</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Adab</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sitch</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (targetcopd): a cluster-randomised controlled trial</article-title>. <source>Lancet Respir Med</source><year>2016</year>;<volume>4</volume>:<fpage>720</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(16)30149-7</pub-id><pub-id pub-id-type="pmid">27444687</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lambe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Adab</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname><given-names>RE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care</article-title>. <source>Thorax</source><year>2019</year>;<volume>74</volume>:<fpage>730</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2018-212148</pub-id><pub-id pub-id-type="pmid">31285359</pub-id><pub-id pub-id-type="pmcid">PMC6703126</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haroon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Adab</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dickens</surname><given-names>AP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of COPD case finding on clinical care: a prospective analysis of the targetCOPD trial</article-title>. <source>BMJ Open</source><year>2020</year>;<volume>10</volume>:<elocation-id>e038286</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2020-038286</pub-id><pub-id pub-id-type="pmcid">PMC7537458</pub-id><pub-id pub-id-type="pmid">33020099</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>COPD</collab></person-group>. <article-title>MedicineInsight post-market surveillance report number 11: NPS medicinewise: Sydney</article-title>. <comment>n.d.</comment><comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-COPD-Post-Market-Surveillance-2017-Report.pdf">https://www.nps.org.au/assets/NPS/pdf/MedicineInsight-COPD-Post-Market-Surveillance-2017-Report.pdf</uri></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Decramer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brusselle</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Buffels</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Copd awareness survey: do Belgian pulmonary physicians comply with the gold guidelines 2010?</article-title><source>Acta Clin Belg</source><year>2013</year>;<volume>68</volume>:<fpage>325</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.2143/ACB.3403</pub-id><pub-id pub-id-type="pmid">24579239</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Echazarreta</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Arias</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Del Olmo</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence of COPD in 6 urban clusters in Argentina: the EPOC.AR study</article-title>. <source>Arch Bronconeumol (Engl Ed)</source><year>2018</year>;<volume>54</volume>:<fpage>260</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.arbres.2017.09.018</pub-id><pub-id pub-id-type="pmid">29221827</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaur</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Aggarwal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gogtay</surname><given-names>J</given-names></string-name></person-group>. <article-title>Understanding perception of chronic obstructive pulmonary disease among general practitioners, physicians, and pulmonologists in India: results from a face-to-face survey</article-title>. <source>Perspect Clin Res</source><year>2016</year>;<volume>7</volume>:<fpage>100</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4103/2229-3485.179438</pub-id><pub-id pub-id-type="pmid">27141477</pub-id><pub-id pub-id-type="pmcid">PMC4840790</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Woodruff</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Bleecker</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical significance of symptoms in smokers with preserved pulmonary function</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>1811</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1505971</pub-id><pub-id pub-id-type="pmid">27168432</pub-id><pub-id pub-id-type="pmcid">PMC4968204</pub-id></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function</article-title>. <source>N Engl J Med</source><year>2022</year>;<volume>387</volume>:<fpage>1173</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2204752</pub-id><pub-id pub-id-type="pmid">36066078</pub-id><pub-id pub-id-type="pmcid">PMC9741866</pub-id></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wong</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Tafuro</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Azam</surname><given-names>Z</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Misdiagnosis of heart failure: a systematic review of the literature</article-title>. <source>J Card Fail</source><year>2021</year>;<volume>27</volume>:<fpage>925</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardfail.2021.05.014</pub-id><pub-id pub-id-type="pmid">34048921</pub-id></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walters</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Johns</surname><given-names>DP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD</article-title>. <source>Thorax</source><year>2008</year>;<volume>63</volume>:<fpage>408</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2007.082859</pub-id><pub-id pub-id-type="pmid">18024537</pub-id></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group>. <article-title>General availability of peak flow measurement spirometry at the primary health care level</article-title>. <year>2020</year>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/data/gho/data/indicators/indicator-details/GHO/general-availability-of-peak-flow-measurement-spirometry-at-the-primary-health-care-level">https://www.who.int/data/gho/data/indicators/indicator-details/GHO/general-availability-of-peak-flow-measurement-spirometry-at-the-primary-health-care-level</uri></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Overington</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>YC</given-names></string-name>, <string-name name-style="western"><surname>Abramson</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions</article-title>. <source>J Thorac Dis</source><year>2014</year>;<volume>6</volume>:<fpage>1586</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2072-1439.2014.11.25</pub-id><pub-id pub-id-type="pmid">25478199</pub-id><pub-id pub-id-type="pmcid">PMC4255168</pub-id></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Berner</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Graber</surname><given-names>ML</given-names></string-name></person-group>. <article-title>Overconfidence as a cause of diagnostic error in medicine</article-title>. <source>Am J Med</source><year>2008</year>;<volume>121</volume>:<fpage>S2</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjmed.2008.01.001</pub-id><pub-id pub-id-type="pmid">18440350</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>ARTP COVID19 Group</collab></person-group>. <article-title>Association for respiratory technology and physiology (ARTP) - guidelines for recommencing physiological services during the coronovirus disease 2019 (COVID-19) endemic phase. Version 5.1 (August 2020 update)</article-title>. <year>2020</year>.</mixed-citation></ref><ref id="R78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Saunders</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Haynes</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>How local SARS-CoV-2 prevalence shapes pulmonary function testing laboratory protocols and practices during the COVID-19 pandemic</article-title>. <source>Chest</source><year>2021</year>;<volume>160</volume>:<fpage>1241</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2021.05.011</pub-id><pub-id pub-id-type="pmid">34004155</pub-id><pub-id pub-id-type="pmcid">PMC8123530</pub-id></mixed-citation></ref><ref id="R79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Borg</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Osadnik</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Pulmonary function testing during SARS-cov-2: an ANZSRS/TSANZ position statement</article-title>. <source>Respirology</source><year>2022</year>;<volume>27</volume>:<fpage>688</fpage>&#8211;<lpage>719</lpage>. <pub-id pub-id-type="doi">10.1111/resp.14340</pub-id><pub-id pub-id-type="pmid">35981737</pub-id><pub-id pub-id-type="pmcid">PMC9539179</pub-id></mixed-citation></ref><ref id="R80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stanojevic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Beaucage</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Comondore</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Resumption of pulmonary function testing during the COVID-19 pandemic</article-title>. <source>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</source><year>2022</year>;<volume>6</volume>:<fpage>78</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1080/24745332.2021.2010478</pub-id></mixed-citation></ref><ref id="R81"><label>81</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Primary Care Respiratory Society (PCRS)</collab></person-group>. <article-title>Spirometry in primary care. guidance on reinstating spirometry in England</article-title>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_PCRS_spiro_re-start_FINAL2.pdf">https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_PCRS_spiro_re-start_FINAL2.pdf</uri> [Accessed <comment>23 Jan 2023</comment>].</mixed-citation></ref><ref id="R82"><label>82</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Association for Respiratory Technology and Physiology (ARTP)</collab></person-group>. <article-title>Statement for the NHS national respiratory programme. Task and finish group. Recommendations for undertaking risk-managed spirometry</article-title>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_PCRS_spiro_re-start_FINAL2.pdf">https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_PCRS_spiro_re-start_FINAL2.pdf</uri> [Accessed <comment>23 Jan 2023</comment>].</mixed-citation></ref><ref id="R83"><label>83</label><mixed-citation publication-type="webpage"><article-title>Recommendation from ERS group 9.1 (respiratory function technologists/ scientists). Lung function testing during COVID-19 pandemic and beyond</article-title>. <comment>Available</comment>: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medicine.usask.ca/respiratoryresearch/documents/ers-9.1-statement-on-lung-function-during-covid-19-final-with-contributors.pdf">https://medicine.usask.ca/respiratoryresearch/documents/ers-9.1-statement-on-lung-function-during-covid-19-final-with-contributors.pdf</uri> [Accessed <comment>3 Feb 2023</comment>].</mixed-citation></ref><ref id="R84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perret</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Vicendese</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Simons</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Ten-year prediction model for post-bronchodilator airflow obstruction and early detection of COPD: development and validation in two middle-aged population-based cohorts</article-title>. <source>BMJ Open Respiratory Research</source><year>2021</year>;<volume>8</volume>:<elocation-id>e001138</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjresp-2021-001138</pub-id><pub-id pub-id-type="pmcid">PMC8640628</pub-id><pub-id pub-id-type="pmid">34857526</pub-id></mixed-citation></ref><ref id="R85"><label>85</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Lung Foundation Australia</collab></person-group>. <source>Transforming the agenda for COPD: a path towards prevention and lifelong lung health - Lung Foundation Australia&#8217;s Blueprint for Action on Chronic Obstructive Pulmonary Disease (COPD) 2022-2025</source>. <publisher-loc>Milton, Queensland</publisher-loc>: <publisher-name>Lung Foundation Australia</publisher-name>, <year>2022</year>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>